These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 3479050)

  • 1. [Tumor markers in human breast cancer].
    Takami H; Shikata J
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):2998-3003. PubMed ID: 3479050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
    Forti E; Wolf D; Melia M
    Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
    Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of immunohistochemical markers in the diagnosis of carcinoma of the breast].
    Bussolati G
    Minerva Chir; 1988 Sep; 43(18 Suppl):5-7. PubMed ID: 3226595
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of tumor marker CA15-3 in breast cancer].
    Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
    Silver HK; Archibald BL; Ragaz J; Coldman AJ
    Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
    Wu JT
    Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers in breast cancer].
    Harada Y; Ohuchi N; Ishida T; Ohnuki K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid receptors in breast cancer.
    Desombre ER
    Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.